Abstract:Ziyu Li, Yuling An, Lijuan Li, Huimin Yi Department of Surgical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, People's Republic of China Correspondence: Huimin Yi, Department of Surgical Intensive Care Unit, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510630, People's Republic of China, Email Purpose: Intracranial infection after neurosurgery is one of the most serious complications, especially extensively drug-resistant (XDR) Acinetobacter baumannii ( A. baumannii ) seriously affects the prognosis of patients. At present, there is little experience in the treatment of this infection and limited effective treatment options, like tigecycline or polymyxin B. Therefore, this report aims to describe the efficacy of tigecycline combined with polymyxin B by intrathecal (ITH) injection in the treatment of XDR intracranial infection with A. baumannii . Methods: We report a case of intracranial infection with XDR A. baumannii after ventricular drainage, treated by daily ITH and intravenous (IV) tigecycline, combined with polymyxin B ITH route. Moreover, tigecycline and polymyxin B treatments for XDR intracranial infection with A. baumannii that were reported in the literature were also reviewed and summarized. Results: The white blood cells (WBCs) of the patient's cerebrospinal fluid dropped to normal, and the symptoms of intracranial infection disappeared. The patient finally obtained good clinical results and transferred to the local hospital. Conclusion: The polymyxin B ITH route is an ideal treatment strategy for XDR A. baumannii . The IV plus ITH tigecycline may be an effective treatment option. However, more researches should be conducted to confirm our observation. Keywords: intracranial infection, Acinetobacter baumannii , intrathecal injection of polymyxin B, tigecycline Intracranial infection is a common serious complication after neurosurgery. The infection rate is about 1.50% to 6.6%, and the fatality rate is 3.8% to 30%. 1,2 Clinical studies have shown that ventricular drainage is one of the important factors leading to intracranial infection after neurosurgery, and other risk factors include trauma, craniotomy and cerebrospinal fluid (CSF) leakage. 3 Gram-positive bacteria and gram-negative bacteria are the main bacteria that cause intracranial infection. Among them, Acinetobacter baumannii ( A. baumannii ) intracranial infections are on the rise, which represent 3.6% to 11.2% of nosocomial intracranial infection cases. 4 The mortality rate of intracranial infection with A. baumannii is reaching up to 71%, which suggests a poor prognosis. 5 In China Antimicrobial Surveillance Network (CHINET) data, the meropenem-resistant rate of A. baumannii increased from 39.0% in 2005 to 73.4% in 2020. 6 Faced with such a high mortality rate and drug resistant rate, it is urgent to treat intracranial infections caused by A. baumannii . Using intravenous (IV) anti-infective drugs alone cannot effectively treat intracranial infections because most drugs cannot enter the central nervous system (CNS). According to recent reports on the treatment of CNS infections, intraventricular (IVT)/intrathecal (ITH) antibiotics showed a good efficacy of extensively drug-resistant (XDR) A. baumannii . Current reports on IVT/ITH drugs are mainly colistin and tigecycline. 4,5,7–9 Karaiskos et al reported the incidence of neurotoxicity for colistin was 11%, with the most significant adverse effect being chemical ventriculitis and meningitis, which provoked a serious dilemma for the clinician. 4 However, the studies showed that the incidence of neurotoxicity for polymyxin B was 7%, which is even lower. 10,11 Tigecycline is the first clinically available drug among glycylcycline class of antibiotics. Studies have shown that it has a good antibacterial effect on A. baumannii and Klebsiella pneumoniae . 12,13 With a poor penetration through the blood brain barrier, the serum concentration of tigecycline in the CSF is only 11%. 14 Therefore, IV tigecycline is not recommended. ITH tigecycline may be a viable alternative for the treatment of intracranial infections because of its low incidence of CNS adverse reactions. 15 At present, the relevant reports are all small-sample studies or case reports. In this case report, we report a patient with intracranial infection after ruptured hemorrhage of an intracranial aneurysm. The continuous ITH tigecycline and polymyxin B was successful. This report shares the experience. In addition, -Abstract Truncated-

Effectiveness of combination therapy with intrathecal or intraventricular administration of polymyxin B for hospital-acquired central nervous system infections caused by carbapenem-resistant Acinetobacter baumannii: A retrospective study

Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii : a retrospective cohort study

Efficacy of Intravenous Plus Intrathecal/intracerebral Ventricle Injection of Polymyxin B for Post-Neurosurgical Intracranial Infections Due to MDR/XDR Acinectobacter Baumannii: a Retrospective Cohort Study

Intrathecal or Intraventricular Antimicrobial Therapy for Post-Neurosurgical Intracranial Infection Due to Multidrug-Resistant and Extensively Drug-Resistant Gram-negative Bacteria: A Systematic Review and Meta-Analysis

Intraventricular Plus Systemic Antibiotic Therapy for Treating Polymyxin-Resistant Klebsiella Pneumoniae Ventriculitis: A Case Report

Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant <i>Pseudomonas</i> aeruginosa Infection

Treatment of Carbapenem-Resistant Multidrug-Resistant Gram-Negative Bacilli with Intracerebroventricular Injection of Polymyxin B A Retrospective study

Intraventricular or intrathecal polymyxin B for treatment of post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria: a 8-year retrospective study

Clinical Outcomes and Safety of Intravenous Polymyxin B-based Treatment in Critically Ill Patients with Carbapenem-resistant Acinetobacter baumannii Nosocomial Pneumonia.

Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection

Polymyxin for the Treatment of Intracranial Infections of Extensively Drug-Resistant Bacteria in Children after Neurosurgical Operation

Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report

Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis

Intrathecal Injection of Tigecycline and Polymyxin B in the Treatment of Extensively Drug-Resistant Intracranial Acinetobacter baumannii Infection: A Case Report and Review of the Literature

Outcome Following the Treatment of Ventriculitis Caused by Multi/Extensive Drug Resistance Gram Negative Bacilli; Acinetobacter baumannii and Klebsiella pneumonia

Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-Resistant Klebsiella Pneumoniae

Treatment efficacy of tigecycline in comparison to cefoperazone/sulbactam alone or in combination therapy for carbapenenm-resistant <i>Acinetobacter baumannii</i> infections

Successful Treatment of Ventriculitis Caused by MDR/XDR Gram-Negative Bacillus Using Ceftazidime/Avibactam: Case Series and Literature Review

Treatment efficacy of tigecycline in comparison to cefoperazone/ sulbactam alone or in combination therapy for carbapenenm-resistant Acinetobacter baumannii infections.

[The Efficacy and Safety of Different Antimicrobial Regimens in Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections].

Ceftazidime-avibactam-based Combination Therapy for Hospital-Acquired Central Nervous System Infections Caused by Carbapenem-Resistant Klebsiella Pneumoniae.